P 9808

Drug Profile

P 9808

Alternative Names: Porphogen; Porphozym

Latest Information Update: 19 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zymenex A/S
  • Class
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute intermittent porphyria

Most Recent Events

  • 01 Apr 2006 P 9808 is available for licensing (http://www.zymenex.com)
  • 01 Apr 2006 Discontinued - Preclinical for Acute intermittent porphyria in Sweden (SC)
  • 01 Apr 2006 Discontinued - Phase-II for Acute intermittent porphyria in Sweden (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top